GUMDROP : A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Created by Nancy Dawson, last modified on Aug 31, 2012

Description:

The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.

Link:

Provide Expanded Access to MDV3100 ...

Site:

Georgetown University Hospital

Principal Investigator:

Dr. Nancy A. Dawson